Now a days, market is flooded with combination of drugs in various dosage forms, but lack of official methods to quantify them. A single dissolution test method for the analysis of combined dosage form is preferred for simplification of quality control testing.
INTRODUCTION
Dissolution is considered as one of the most routinely performed quality control test on dosage forms to ensure uniformity and reproducibility of production batches.
Process parameters and ingredients are optimized during product development [1] [2] [3] , whether changes made in the formulations or their manufacturing processes are likely to affect the performance in the clinic or not are decided using dissolution methods 4 . An immediate release dosage form is designed to deliver the drug rapidly into systemic circulation. Hence, the dissolution may become the rate limiting step for its absorption. The absorption of a drug substance may vary by diverse parameters like its solubility and permeability in the conditions associated with the gastrointestinal (GI) tract after oral administration [5] [6] [7] . Keeping all these points into consideration, there is a need to put more research efforts on developing in vitro GI fluids that mimics the in-vivo conditions. The discriminative dissolution method has ability to differentiate the dissolution profiles between manufacturer process variations and product composition variations [8] [9] [10] .
Fenofibrate, chemically known as Isopropyl 2-[4-(4-chlorobenzoyl)2-phenoxy] methyl
propanoate, is a fibric acid derivative with lipid regulating properties striving its therapeutic effects through activation of peroxisome proliferator activated receptor α has been a challenge; if possible a single dissolution method is preferred to simplify quality control testing procedures [13] [14] [15] . Few analytical methods were reported for simultaneous quantification of atorvastatin calcium and Fenofibrate by HPLC and spectrophotometric method [16] [17] [18] [19] . The facility of derivative spectroscopy may be used with minimum error for the quantification of one analyte 20, 21 . 
MATERIALS AND METHODS

Materials
Instrumentation
Double beam 1800 UV-Visible spectrophotometer (Shimadzu, Japan), dissolution apparatus (Electro lab TDT-08L), analytical balance (Shimadzu AUX 220, Japan), tablet compression machine (Lab press-CIP machineries, Ahmedabad, India), hardness tester (Secor, Hyderabad, India) pH meter (Elico, Hyderabad) and ultrasonic cleaner were used for the study (Calibration of instruments were done according to standard procedure)
Analytical method
First-order-derivative overlaid spectra of atorvastatin calcium and fenofibrate denotes that there was no zero crossing point for atorvastatin calcium for quantification of fenofibrate ( Figure 2 ). Hence first derivative spectrum was not suitable for u n c o r r e c t e d p r o o f simultaneous estimation and this problem was minimized by second-order-derivative method, which permitted to select the suitable wavelengths that make the quantification possible with zero crossing, where fenofibrate zero absorbance at 281 nm, while atorvastatin calcium gave the significant derivative response likewise atorvastatin gave zero absorbance at 296 nm, while fenofibrate gave the significant derivative response. Therefore, 281 nm and 296 nm were selected for estimation of atorvastatin calcium and fenofibrate, respectively.
Dissolution test conditions
The log P values of atorvastatin calcium and fenofibrate were 6.36 and 5.28, respectively indicating low water solubility so the development of a single dissolution method for this combination is challenge and a single in vitro dissolution studies were not reported for this combination along these lines, an attempt is made to develop and validate a single dissolution test for atorvastatin calcium and fenofibrate in combined tablets.
Evaluated the dissolution profiles of atorvastatin calcium (10 mg) and fenofibrate ) and discrete product composition (with/with-out disintegrant).
Scrutinizing the dissolution-profiles in test conditions followed by data was estimated with factors of comparison (f1 and f2).
u n c o r r e c t e d p r o o f
Stability determination
Sample solutions withdrawn for the optimized dissolution medium were analyzed at 0 time, consonantly samples were kept for 24 hours and 48 hours and analyzed by proposed method.
Validation of the dissolution method
The validation of dissolution method is required to ensure that a proposed dissolution method is scientifically and experimentally sound, obtaining the results of specificity, linearity, accuracy and precision as per standard guidelines.
The method specificity was assessed by comparing the spectra obtained from the commercial formulations and the synthetic mixture from standard solutions by preparing similar dose ratio of synthetic and tablet dosage form. Then analytical method was applied in order to check if any component of the formulation could generate a response or an absorption wavelength similar to the drugs.
Linearity was determined by standard concentrations of atorvastatin (2-12 µg/mL) and fenofibrate (1-35 µg/mL) were quantified with second derivative spectrophotometric technique, then absorbance was recorded and calibration curve was constructed by plotting the analyte response versus the drug concentrations.
Intra-day and inter-day precision studies were evaluated as per ICH guidelines, in which six tablets were subjecting to the dissolution test conditions, on the same day (intra-day precision) and for three consecutive days (inter-day precision), then % RSD was calculated.
Accuracy studies were conducted using standard addition method where the known amount of drugs at 80, 100 and 120% of the formal assay of atorvastatin and fenofibrate to the placebo sample in the dissolution medium, further subjected to contemplated method; then percentage recovery and relative standard deviation (% RSD) were computed for each concentration.
RESULTS AND DISCUSSION
Development of dissolution method
The selection of a dissolution test method was based on dissolution profiles of atorvastatin (10 mg) and fenofibrate (145 mg) bulk drug filled capsules using a USP type 2 apparatus at a paddle speed of 50 rpm and selection of a dissolution medium u n c o r r e c t e d p r o o f to adequate solubility and stability of both atorvastatin calcium and fenofibrate was demand for this dissolution method. The log P values of atorvastatin calcium and fenofibrate respectively were 6.36 and 5.28, denoting low water solubility. Several compendia dissolution media were screened; these include various buffer media (pH 1.2 to 7.4), surfactant media and several bio-relevant media, However, the results showed that the dissolution rate of atorvastatin was found to be maximum in weak acidic buffers because of the specific interaction but fenofibrate dissolution rate was less than 2% in all buffers, indicating that fenofibrate dissolution was independent of pH due to absence of ionizable groups (Table I ). Both drugs were showed higher dissolution in 0.5% w/v sodium lauryl sulphate medium than other dissolution media.
Dissolution medium with low concentration of sodium lauryl sulphate may resemble gastric environment of our body, and hence this medium is useful for correlating invitro dissolution behavior of atorvastatin and fenofibrate combined dosage form with their in-vivo performance. This medium can also be a useful quality control tool and the selected dissolution test conditions are: USP apparatus 2 at paddle speed 50 rpm in a medium of 0.5% w/v sodium lauryl sulphate. Therefore, dissolution studies were performed for commercial tablets (Atocor and Fibator) in optimised dissolution test conditions.
In-vitro dissolution profiles of commercial tablets
Dissolution studies on Atocor and Fibator tablets were enforced under the optimised dissolution test medium of 0.5% w/v sodium lauryl sulphate, by using USP type 2 apparatus at paddle speed of 50 rpm at temperature 37 ± 0.5  C and these results are obtained in Figure 3 and 4, indicated that about 85% of both atorvastatin and fenofibrate were released in 45 min from the two brands. In fact, fenofibrate exhibited only 50% dissolution in 60 min (Table I) . On the other hand, tablets exhibited 85% dissolution in 45 min; it means that the in active ingredients in the tablets also supported the dissolution. Such a factor should also be kept in mind, while optimising the dissolution conditions. Atorvastatin components of the tablet formulation exhibited 88% dissolution in 45 min, whereas the pure drug exhibited and disintegrant (with vs without) were shown in Figure 5 followed by data of dissolution was compute with the factors of comparison using 6 points; among these, one point was found to specify the drug release more than 85% (Table II) . These results confirmed that the dissolution test procedure has ability to discriminate for distinct composition and process, based on these results, 0.5% w/v sodium lauryl sulphate medium has discriminating power.
Stability determination of atorvastatin and fenofibrate in dissolution medium
The stability of drugs in dissolution medium at different time periods was calculated in order to demonstrate the integrity of the drugs and obtained in Table III, notified that both drugs were stable under dissolution test conditions. The change in drug content was not assessed and likewise no evidence of degradation denotes that the solutions were stable for more than 48 h.
Dissolution method validation
Linearity
The linearity was assessed by the regression equation of calibration curve method.
The responses for atorvastatin at 281 nm were found to be linear in the concentration range of 2-12 μg/mL, with a correlation co-efficient (R (Figure 7 ), hence the method was found to be specific.
Precision
The precision evaluation data for the dissolution studies was obtained in Table IV, denoted that percent relative standard deviation values for intra-day and inter-day precision studies were found to be less than 2 and there was no significant differences, which indicates the proposed method was reproducible and precise.
Accuracy
The accuracy assessment data for the dissolution studies was obtained in 
